Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free Bimatoprost vs Lumigan in Open-angle Glaucoma or Ocular Hypertension
2023-504759-28-00Phase 3Completed
- Sponsor
- Genetic
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bimatoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by Genetic. Primary endpoint: Primary: Mean percentage reduction in intraocular pressure from baseline to day 42. Started Feb 2024; status: completed.
02
Drugs
bimatoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2023-504759-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504759-28-00.